4/15
08:18 am
scnx
Scienture granted 180-day extension by Nasdaq to regain compliance [Seeking Alpha]
Low
Report
Scienture granted 180-day extension by Nasdaq to regain compliance [Seeking Alpha]
4/15
08:05 am
scnx
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
Medium
Report
Scienture Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
4/6
08:05 am
scnx
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
Medium
Report
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
3/30
08:46 am
scnx
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update [Yahoo! Finance]
3/30
08:07 am
scnx
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
High
Report
SCIENTURE Reports Year End 2025 Financial Results and Provides Business Update
3/14
01:32 am
scnx
Low
Report
3/11
08:14 am
scnx
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions [Yahoo! Finance]
Medium
Report
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions [Yahoo! Finance]
3/11
08:05 am
scnx
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
High
Report
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
2/24
12:52 pm
scnx
Scienture (NASDAQ:SCNX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $1.50 price target on the stock.
Low
Report
Scienture (NASDAQ:SCNX) is now covered by analysts at Maxim Group. They set a "buy" rating and a $1.50 price target on the stock.
2/3
08:23 am
scnx
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium [Yahoo! Finance]
Medium
Report
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium [Yahoo! Finance]
2/3
08:05 am
scnx
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
Low
Report
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium